Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 1
2006 5
2007 3
2008 2
2009 4
2010 4
2011 3
2012 4
2013 6
2014 10
2015 5
2016 2
2017 5
2018 2
2019 2
2020 7
2021 13
2022 4
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Association of microbiota with cancer treatment.
Yoshimura K. Yoshimura K. Int J Clin Oncol. 2023 Mar;28(3):341-346. doi: 10.1007/s10147-023-02302-4. Epub 2023 Feb 27. Int J Clin Oncol. 2023. PMID: 36843139 Review.
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Hamada K, et al. Among authors: yoshimura k. Front Immunol. 2023 May 3;14:1164724. doi: 10.3389/fimmu.2023.1164724. eCollection 2023. Front Immunol. 2023. PMID: 37207204 Free PMC article.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T. Masuda J, et al. Among authors: yoshimura k. J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126. J Immunother Cancer. 2023. PMID: 37709297 Free PMC article. Clinical Trial.
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: yoshimura k. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
[Genetic diagnosis of intestinal cancer].
Yoshimura K, Oka M, Tani K. Yoshimura K, et al. Nihon Rinsho. 2010 Aug;68 Suppl 8:451-7. Nihon Rinsho. 2010. PMID: 20976922 Review. Japanese. No abstract available.
89 results